Literature DB >> 3707814

Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.

S R Smith, M J Kendall.   

Abstract

We have studied the influence of therapeutic plasma concentrations of theophylline on some of the unwanted responses to intravenous terbutaline in normal subjects. There was a significantly greater fall in serum potassium and rise in plasma glucose, pulse rate and systolic blood pressure in response to an intravenous infusion of terbutaline when theophylline was present compared with when terbutaline was given alone. These drugs are commonly used together in the treatment of acute asthma and potentiation of side effects may be hazardous. We suggest monitoring of the serum potassium when these drugs are used together during acute exacerbations of asthma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3707814      PMCID: PMC1400932          DOI: 10.1111/j.1365-2125.1986.tb05221.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma.

Authors:  P D Stolley
Journal:  Am Rev Respir Dis       Date:  1972-06

2.  Responsiveness to beta-adrenergic receptor stimulation: the effects of age are cardioselective.

Authors:  M J Kendall; K L Woods; M R Wilkins; D J Worthington
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

3.  Cardiovascular effects of two different xanthines in healthy subjects. Studies at rest, during exercise and in combination with a beta-agonist, terbutaline.

Authors:  T B Conradson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Airway and metabolic resistance to intravenous salbutamol: a study in normal man.

Authors:  S T Holgate; W A Stubbs; P J Wood; E S McCaughey; K G Alberti; A E Tattersfield
Journal:  Clin Sci (Lond)       Date:  1980-09       Impact factor: 6.124

5.  Homogeneous enzyme immunoassay for theophylline in serum and plasma.

Authors:  J Chang; S Gotcher; J B Gushaw
Journal:  Clin Chem       Date:  1982-02       Impact factor: 8.327

6.  Effect of intravenous infusion of salbutamol on ventilatory response to carbon dioxide and hypoxia and on heart rate and plasma potassium in normal men.

Authors:  A G Leitch; L J Clancy; J F Costello; D C Flenley
Journal:  Br Med J       Date:  1976-02-14

7.  Airway and metabolic responsiveness to intravenous salbutamol in asthma: effect of regular inhaled salbutamol.

Authors:  J E Harvey; C J Baldwin; P J Wood; K G Alberti; A E Tattersfield
Journal:  Clin Sci (Lond)       Date:  1981-05       Impact factor: 6.124

8.  Metabolic effects of intravenous salbutamol in the course of acute severe asthma.

Authors:  S G Nogrady; J P Hartley; A Seaton
Journal:  Thorax       Date:  1977-10       Impact factor: 9.139

9.  Diuretic-induced ventricular ectopic activity.

Authors:  O B Holland; J V Nixon; L Kuhnert
Journal:  Am J Med       Date:  1981-04       Impact factor: 4.965

10.  Metabolic and cardiovascular side effects of the beta 2-adrenoceptor agonists salbutamol and rimiterol.

Authors:  P J Phillips; A E Vedig; P L Jones; M G Chapman; M Collins; J B Edwards; T C Smeaton; B M Duncan
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

View more
  3 in total

Review 1.  Adverse reactions and interactions with theophylline.

Authors:  M H Skinner
Journal:  Drug Saf       Date:  1990 Jul-Aug       Impact factor: 5.606

2.  Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.

Authors:  J H Jonkman; L Borgström; W J van der Boon; O E de Noord
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

3.  Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.

Authors:  K F Whyte; C Reid; G J Addis; R Whitesmith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.